0130 GMT - IHH Healthcare's earnings may stay resilient in 2H, given improvements in inpatient volumes, Affin Hwang IB analyst Andrew Lim says in a note. The healthcare provider looks well on track to achieve 29% EPS growth for 2024, supported by a low 2023 base and stronger contributions from Malaysia, Turkey and India, he reckons. Ringgit appreciation could have minimal impact on IHH, as conservative estimates for SGD, which makes up nearly 50% of its profit before tax were already factored in, he adds. IHH plans to add about 4,000 beds over the next four years, meeting strong demand, Lim notes. Affin Hwang raises IHH's target price to MYR8.30 from MYR7.40, and maintains a buy rating given its earnings growth prospects and undemanding valuation. Shares are unchanged at MYR7.22. (yingxian.wong@wsj.com)
(END) Dow Jones Newswires
October 09, 2024 21:30 ET (01:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。